Chemo & Other Therapies
Chemotherapy for Acute Myeloid Leukemia
- Daunorubicin and cytarabine
- Daunorubicin, cytarabine and thioguanine
- Cytarabine and idarubicin
- Cytarabine and mitoxantrone
- Cytarabine or methotrexate intrathecally for known
- CNS infiltration
Other drugs
- Etoposide
- Amsacrine
- Mitoxantrone
- Idarubicin (new)
- Homoharringtonine
Chemotherapy for Acute Lymphocytic Leukemia
- High-dose methotrexate or intrathecal methotrexate for CNS prophylaxis
- The average length of treatment is between one and one-half and three years for ALL
- Vincristine, prednisone, doxorubicin or daunorubicin
- Vincristine, prednisone, asparaginase, daunorubicin
- Vincristine, prednisone, asparaginase, doxorubicin
- Vincristine, prednisone, doxorubicin, intrathecal methotrexate
- Methotrexate, vincristine, asapraginase, dexamethasone
- Vincristine, prednisone, anthracycline, with or without
- asparaginase
Maintenance chemotherapy with combinations of the following:
- 6 mercaptopurine
- Cyclophosphamide
- Cyatarabine
- Prednisone
- Vincristine
- Carmustine
- Daunorubicin
- Doxorubicin
- Teniposide
Chemotherapy for Chronic Lymphocytic Leukemia
- Chlorambucil (oral) with or without prednisone
- Cytoxan (oral) with or without prednisone
- Fludarabine (under clinical evaluation for refractory CLL)
- Combinations
- COP (cytoxan, vincristine, prednisone)
Key words
- Induction
Administering chemotherapy to obtain remission - Nadir
The lowest number of stem cells in the bone marrow; the point in chemotherapy administration when the patient is at greatest risk of developing infection; also called myelosuppression - Remission
The clinical disappearance of leukemia, characterized by a normal peripheral blood count, less than 5% blasts in the bone marrow, no clinical signs or symptoms of leukemia, and no evidence of CNS or visceral infiltration by leukemia - Consolidation
Administering high doses of chemotherapy for a short term to maintain remission - Maintenance
Administering relatively low doses of chemotherapy for a long term to maintain remission
Hormones
Prednisone in combination with alkylating agents
Biological Response Modifiers (under clinical evaluation)
- Bone Marrow Transplantation (autologous = from the patient; allogeneic = from another patient); also called ABMT
- Interleukin-2 (under clinical evaluation)
- Colony stimulating factors (CSF) (under clinical evaluation)